Follow us on:

Goodbody Health early detection substantially improves patient outcomes (Interview)

Goodbody Health Inc. (CSE: GDBY / AQSE: GDBY / FRA: 484 / OTC: SCNNF) Scientific Advisory Committee Member Dr Jamie Brosch joins DirectorsTalk Interviews to share his views on the company.

Jamie provides us with some background as a highly experienced GP, shares his views on Goodbody’s partnership with independent pharmacies supporting the over stretched NHS, how the company differs from others in the market, how blood tests will help an individual to start managing their health, thoughts on the GP referral scheme, how Jamie contributes to the Goodbody Scientific Advisory Committee and how results can impact on a person’s long term health.

Goodbody Health Inc. are a wellness company, focusing on the Health and Wellness of customers through the local community by the introduction and use of cutting edge diagnostic equipment.

Find more news, interviews, share price & company profile here for:Goodbody Health

Share this interview

Other Interviews

Goodbody Health undervalued yet good fundamentals (VIDEO) June 14, 2022
Why is the outlook for Goodbody Health ‘tremendously exciting and hugely positive’ (VIDEO) May 27, 2022
Goodbody Health signing up pharmacies as fast as they can (VIDEO) May 6, 2022
Goodbody Health products included on FSA Novel Foods Register (Interview) April 1, 2022
A Blood MOT has never been easier to prevent heart disease (Interview) March 11, 2022
Goodbody Health relieving stresses and strains on the NHS (Interview) March 1, 2022
Goodbody Health Phytovista Laboratories extends its ISO 17025 UKAS accreditation (Interview) February 11, 2022
Goodbody Health a pivotal moment in community pharmacy (Interview) January 26, 2022
Goodbody Health providing best in class wellness solutions (Interview) January 13, 2022

More News

Goodbody Health George Thomas steps up as new CEO December 1, 2022
Goodbody Health agreement with Allied Pharmacies adds 17 Clinics October 19, 2022
Goodbody Health announces distribution agreement with Tasso October 3, 2022
Goodbody Health H1 revenue 52% higher than 2021 August 19, 2022
Goodbody Health announces Annual General and Special Meeting of Shareholders July 14, 2022
Goodbody Health launches genetic risk testing for cancer and cardiovascular diseases June 20, 2022
Goodbody Health passes Care Quality Commission registration June 16, 2022
Goodbody Health undervalued yet good fundamentals (VIDEO) June 14, 2022
Goodbody Health to de-list from CSE to better align corporate structure June 10, 2022
Why is the outlook for Goodbody Health ‘tremendously exciting and hugely positive’ (VIDEO) May 27, 2022

Search

Useful links

Disclaimer

You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular stock, share, security, portfolio of securities, transaction, investment strategy, or other matter. We openly disclose that we and our contributors may have interests in investments and/or providers of services referred to within the website and that we receive remuneration from certain of the companies referred to on this website.

© 2024 – DirectorsTalk Interviews. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.